Business
Immune Therapeutics to Present at the 7th Annual LD Micro Invitational
Immune Therapeutics to Present at the 7th Annual LD Micro Invitational.
About this update from Biostax Corp.
[{"type":"text","content":"LOS ANGELES, CA / ACCESSWIRE / June 5, 2017 / Immune Therapeutics, Inc. (OTCQB: IMUN), a specialty pharmaceutical company focused on developing and commercializing our novel patented, affordable, non-toxic therapy for the management of cancer, HIV, autoimmune diseases, and other inflammatory conditions, today announced that it will be presenting at the 7th annual LD Micro Invitational on Wednesday, June 7 at 9:00 AM PST / 12:00 PM EST. Chief Executive Officer, Noreen Griffin, will be giving the presentation and meeting with investors.Immune Therapeutics recently announced that it has received NAFDAC (National Agency for Food and Drug Administration and Control) approval to market and distribute LodonalTM, the Company's breakthrough treatment for HIV/AIDS in Nigeria. The Company and its strategic partners plan to immediately initiate sales activities of this first-to-market opportunity.\"With Immune Therapeutics' recently announced debt restructuring, the company is well positioned to move forward with its business plan, which calls for a significant ramp-up in revenues and achievement of profitability by the end of the fourth quarter,\" stated Ms. Griffin. \"In addition to Nigeria, the company expects to obtain regulatory approvals in Kenya, Senegal, and Cote d'Ivoire by the fourth quarter of 2017 or early in 2018. We are very proud of the many achievements this company has made over the past several years and look forward to updating our shareholders on our commercialization strategy followed by the announcement of initial contracts.\" \"This year, not only do we have a record number of companies making their LD Micro debuts, but a record number of companies presenting for the first time in their company's history,\" stated Chris Lahiji, President of LD Micro. \"LD has established itself as the one venue that brings the most influential players from all segments of the market under one roof.\"The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 180 companies in the small / micro-cap space. View Immune Therapeutics' profile here: https://www.ldmicro.com/profile/IMUN Profiles powered by LD Micro - News Compliments of ACCESSWIRE.About Immune Therapeutics, Inc. Immune Therapeutics, Inc. (OTCQB: IMUN) is a clinical-stage biopharmaceutical company developing its proprietary version of lower-dose naltrexone, L...